{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021229","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.407314+00:00","generated_at":"2026-06-15T04:08:19.939983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Trevi Therapeutics reports Q1 net loss of $6.4M; plans three chronic cough trials in H2 2023","bullets":["Net loss of $6.4M in Q1 2023 vs. $7.3M in Q1 2022; cash and equivalents $111.3M.","Plans to initiate Phase 2b trial for chronic cough in IPF, Phase 1b respiratory physiology trial, and Phase 2a refractory chronic cough trial in H2 2023.","Received Notice of Allowance for U.S. patent covering oral nalbuphine ER for chronic cough in IPF, expected expiration 2039.","Completed open-label extension of Phase 2b/3 PRISM trial for prurigo nodularis; will request End of Phase 2 meeting with FDA.","Completed part 1 of human abuse potential study; selected butorphanol dose for part 2."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021229","json":"https://secwatch.observer/filing/0000950170-23-021229.json","markdown":"https://secwatch.observer/filing/0000950170-23-021229.md","text":"https://secwatch.observer/filing/0000950170-23-021229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023021229/0000950170-23-021229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023021229/trvi-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:08:19.939983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d234406f638126c29262261888e949aa3624dc78","claim":"Trevi Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income a net loss of $6.4 million.","evidence_excerpt":"For the first quarter of 2023, the Company reported a net loss of $6.4 million, compared to a net loss of $7.3 million in the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017023021229/0000950170-23-021229-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"a net loss of $6.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}